FDA Says Cephalon's (CEPH) Website Promoting Trisenox Broadens Use and Omits Risks of Drug
Tweet
Share
E-mailGet Alerts CEPH Hot Sheet
Join SI Premium – FREE
FDA just announced Cephalon's (Nasdaq: CEPH) website promoting its trisenox broadens the use of the drug and omits risk.
Shares are now positive following the FDA headlines. The stock last traded at $79.95, up about 0.9 percent from Wednesday's closing price.
Shares are now positive following the FDA headlines. The stock last traded at $79.95, up about 0.9 percent from Wednesday's closing price.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- Hyperfine wins FDA clearance for updated portable MRI software
- Creative Medical completes enrollment in ADAPT back pain trial
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
